Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 11.86M P/E - EPS this Y 59.70% Ern Qtrly Grth -
Income -1.81M Forward P/E - EPS next Y 62.80% 50D Avg Chg -24.00%
Sales 441.25k PEG - EPS past 5Y - 200D Avg Chg -24.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -75.00%
Recommedations 2.50 Quick Ratio 1.54 Shares Outstanding 1.86M 52W Low Chg 7.00%
Insider Own 19.37% ROA -95.59% Shares Float 1.50M Beta -
Inst Own 3.02% ROE - Shares Shorted/Prior 54.30K/104.84K Price 2.13
Gross Margin - Profit Margin - Avg. Volume 3,300,662 Target Price 5.50
Oper. Margin -3,332.34% Earnings Date - Volume 241,386 Change -0.93%
About 60 Degrees Pharmaceuticals, Inc

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

60 Degrees Pharmaceuticals, Inc News
12/24/24 60 Degrees, Tufts Medical Center announces patent license agreement
12/23/24 Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
12/11/24 60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
12/02/24 VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
11/22/24 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
11/14/24 60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates
11/14/24 60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
10/03/24 60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
09/06/24 60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
09/04/24 60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
08/28/24 60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
08/17/24 60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations
08/14/24 60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates
08/14/24 60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
08/12/24 Should You Add 60 Degrees Pharmaceuticals, Inc. (SXTP) to Your Stock Portfolio Right Now?
08/12/24 60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
08/06/24 60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
07/25/24 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support
07/22/24 60 Degrees Pharmaceuticals enters deals for babesiosis treatment trial
07/19/24 60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
DOW GEOFFREY S President and CEO President and CEO Jan 31 Buy 0.375 25,974 9,740 703,599 02/02/24
XU CHERYL Director Director Jan 31 Buy 0.38 200,000 76,000 424,934 02/02/24